PL2328552T3 - Preparaty lipidowe zawierające tiolowany przeciwutleniacz - Google Patents

Preparaty lipidowe zawierające tiolowany przeciwutleniacz

Info

Publication number
PL2328552T3
PL2328552T3 PL09784991T PL09784991T PL2328552T3 PL 2328552 T3 PL2328552 T3 PL 2328552T3 PL 09784991 T PL09784991 T PL 09784991T PL 09784991 T PL09784991 T PL 09784991T PL 2328552 T3 PL2328552 T3 PL 2328552T3
Authority
PL
Poland
Prior art keywords
lipid formulations
thiolated antioxidant
thiolated
antioxidant
lipid
Prior art date
Application number
PL09784991T
Other languages
English (en)
Inventor
Catalin Nistor
Fredrik Tiberg
Krister Thuresson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PL2328552T3 publication Critical patent/PL2328552T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09784991T 2008-08-22 2009-08-21 Preparaty lipidowe zawierające tiolowany przeciwutleniacz PL2328552T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0815435.3A GB0815435D0 (en) 2008-08-22 2008-08-22 Formulations
PCT/GB2009/002054 WO2010020794A1 (en) 2008-08-22 2009-08-21 Lipid formulations comprising a thiolated antioxidant
EP09784991A EP2328552B1 (en) 2008-08-22 2009-08-21 Lipid formulations comprising a thiolated antioxidant

Publications (1)

Publication Number Publication Date
PL2328552T3 true PL2328552T3 (pl) 2013-05-31

Family

ID=39846743

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09784991T PL2328552T3 (pl) 2008-08-22 2009-08-21 Preparaty lipidowe zawierające tiolowany przeciwutleniacz

Country Status (8)

Country Link
US (3) US9668967B2 (pl)
EP (1) EP2328552B1 (pl)
JP (1) JP5612578B2 (pl)
CA (1) CA2734956C (pl)
DK (1) DK2328552T3 (pl)
GB (1) GB0815435D0 (pl)
PL (1) PL2328552T3 (pl)
WO (1) WO2010020794A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
SI1845942T1 (sl) 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
CA2836847C (en) * 2011-05-25 2021-06-29 Camurus Ab Controlled release peptide formulations
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
EP2877155B1 (en) * 2012-07-26 2020-10-28 Camurus AB Opioid formulations
EA034855B1 (ru) * 2012-07-26 2020-03-30 Камурус Аб Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP3106153A1 (en) 2013-06-04 2016-12-21 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN109789214B (zh) 2016-09-27 2022-06-28 卡姆拉斯公司 包含edta烷基铵盐的混合物和制剂
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
EP3743072B1 (en) * 2018-01-22 2023-10-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
EP0643620B1 (en) 1991-10-04 1999-07-21 Gs Development Ab Particles, method of preparing said particles and uses thereof
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
JP4137179B2 (ja) * 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
CA2231273A1 (en) 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
CA2286052A1 (en) 1997-04-17 1998-10-29 Lise Sylvest Nielsen A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
EP1600162A1 (en) 1998-12-22 2005-11-30 Eli Lilly & Company Shelf-stable formulation of glucagon-like peptide-1
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
CA2340757A1 (en) * 1999-07-07 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Delivery of liposomal-encapsulated antioxidants and applications thereof
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
EP1660227B1 (en) 2003-08-04 2012-05-23 Camurus Ab Method for improving the properties of amphiphile particles
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
EP1682091B1 (en) 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
PL1713446T3 (pl) 2004-01-23 2011-05-31 Camurus Ab Nielamelarne trójskładnikowe kompozycje lipidów
ES2309766T3 (es) 2004-06-04 2008-12-16 Camurus Ab Formulaciones liquidas de liberacion lenta.
EP1778187B1 (en) 2004-08-04 2012-05-23 Camurus Ab Compositions forming non-lamellar dispersions
AU2005282773B2 (en) * 2004-09-01 2010-07-08 Maine Standards Company, Llc Stable lipid standards
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
SI1845942T1 (sl) 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
PL1848403T3 (pl) 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
PL1843746T3 (pl) 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) * 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations

Also Published As

Publication number Publication date
EP2328552B1 (en) 2013-01-09
GB0815435D0 (en) 2008-10-01
US20190350841A1 (en) 2019-11-21
CA2734956A1 (en) 2010-02-25
CA2734956C (en) 2017-02-07
EP2328552A1 (en) 2011-06-08
US20110230569A1 (en) 2011-09-22
WO2010020794A1 (en) 2010-02-25
US9668967B2 (en) 2017-06-06
JP5612578B2 (ja) 2014-10-22
US20170281537A1 (en) 2017-10-05
DK2328552T3 (da) 2013-03-11
JP2012500787A (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
IL290077A (en) Improved lipid formulation
PL2328552T3 (pl) Preparaty lipidowe zawierające tiolowany przeciwutleniacz
IL251846A0 (en) lipid preparations
ZA201007612B (en) Lipid composition
GB2459691B (en) Formulations
GB0823269D0 (en) Formulations
EP2420244A4 (en) MEANS TO PROMOTE FATTY CHANGE
GB0821789D0 (en) Formulations
EP2307021A4 (en) FORMULATIONS
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0724193D0 (en) Lipid
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations
GB0807906D0 (en) Formulations
GB0811447D0 (en) Formulations
GB0916106D0 (en) Formulations
GB0823493D0 (en) Formulations
GB0823486D0 (en) Formulations
GB0817079D0 (en) Formulations
GB0816876D0 (en) Formulations